Part 7: Systems of Care - Appendix 1. Writing Group Disclosures

Appendix 1. Writing Group Disclosures
Writing Group Member Employment Research Grant Other Research Support Speakers' Bureau/
Honoraria
Expert Witness Ownership Interest Consultant/
Advisory Board
Other
Katherine M. Berg Beth Israel Deaconess Medical Center NHLBI Grant K23 HL128814 None None None None None None
Khalid Aziz University of Alberta (Canada) None None None None None None University of Alberta (Professor of Pediatrics)†
Farhan Bhanji McGill University (Canada) None None None None None None None
Blair L. Bigham McMaster University (Canada) None None None None None None None
Adam Cheng Alberta Children’s Hospital (Canada) None None None None None None None
Karen G. Hirsch Stanford University American Heart Association (cardiac arrest research)* None None Stroke and TBI cases (not cardiac arrest)* None None None
Amber V. Hoover American Heart Association None None None None None None American Heart Association (Advisor for Science and Health Advancement)†
Michael C. Kurz University of Alabama at Birmingham DOD (DSMB for Pre-Hospital Airway Control Trial [PACT])*; NIH (Co-PI for R21 examining mast-cell degranulation in OHCA)* None Zoll Medical Corp.* None None None None
Eric J. Lavonas Denver Health Emergency Medicine BTG Pharmaceuticals (Denver Health (Dr Lavonas’ employer) has research, call center, consulting, and teaching agreements with BTG Pharmaceuticals. BTG manufactures the digoxin antidote, DigiFab. Dr Lavonas does not receive bonus or incentive compensation, and these agreements involve an unrelated product. When these guidelines were developed, Dr Lavonas recused from discussions related to digoxin poisoning.)† None None None None None American Heart Association (Senior Science Editor)†
Arielle Levy University of Montreal (Canada) None None None None None None None
Yiqun Lin Alberta Children's Hospital (Canada) None None None None None None None
David J. Magid University of Colorado NIH†; NHLBI†; CMS†; AHA† None None None None None American Heart Association (Senior Science Editor)†
Melissa Mahgoub American Heart Association None None None None None None None
Ashish R. Panchal The Ohio State University None None None None None None None
Mary Ann Peberdy Virginia Commonwealth University None None None None None None None
Amber J. Rodriguez American Heart Association None None None None None None None
Comilla Sasson American Heart Association None None None None None None None
Alexis A. Topjian The Children's Hospital of Philadelphia NIH (POCCA trial site PI)* None None None None None None

This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be “significant” if (a) the person receives $10,000 or more during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $10,000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.

*Modest.
†Significant.